Someone might take on a license for either DEP® Irinotecan and...

Someone might take on a license for either DEP® Irinotecan and DEP® Cabazitaxel but given they both need 'further investigation' it won't be for the lofty prices floated about on here over the years ... I guess if someone paid $5 million for each and agreed to absorb all the additional study costs it would be something in the interim and considered a small win in the scheme of things ?


@antibotter 's estimates of $100 million for each DEP® drug ( Post #:65156161 ) was always ambitious pie in the sky predictions IMO and as we now know from the recent company business update, all DEP® Docetaxel business development has been "paused" so it is a dead duck.


It truly is amazing how after all the grandstanding about how the DEP® phase 2 trials supposedly demonstrated 'proof of concept' and/or 'the science is so good' Starpharma appear to be begging regional pharma's now for any contribution to take the DEP® drugs further as big pharma are giving us the cold shoulder (not interested) ?


I also find it interesting that Starpharma are suggesting in this comment below.....

"many regional and country-centric companies have shared a greater interest in partnering at an earlier stage"

....... that the likes of Merck (a multinational company) aren't interested in phase 2 assets or phase 2 assets requiring further investigation (early stage assets) ? Here's one of the numerous examples of our supposed partner Merck's early moves on a phase 1 / 2a asset .....so sadly one might deduce it is not the phase of the asset that is the issue here but perhaps the data / results of our DEP® drugs aren't as great as we thought ?


https://www.fiercebiotech.com/biote...vision-new-opthalmology-assets-3b-eyebioo-buy

_{Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy}


Restoret has already been tested in a phase 1b/2a trial called AMARONE in DME and neovascular age-related macular degeneration. The phase 2b/3 test is slated to begin in the second half of this year.





Extract from Starpharma ASX Business Update 22 May 2024